Humira under the microscope: new registry tracks safety in chinese Crohn's patients

NCT ID NCT05394805

Completed Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This registry study followed 156 Chinese patients with moderate to severe Crohn's disease who were prescribed Humira (adalimumab) by their doctors. The goal was to see how safe and effective the drug is in real-world use over one year. Researchers tracked serious side effects and changes in disease activity. Since Humira is already approved for Crohn's, this study aims to confirm its benefits and risks in a Chinese population.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Humira (adalimumab)
What this could lead to: If successful, this registry could confirm that Humira is safe and effective for treating Crohn's disease in Chinese patients, supporting its continued use.
What could go wrong: This is an observational registry, not a controlled trial, so results may be less definitive. It only follows patients for one year, so long-term effects are not assessed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CROHN'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Crohn disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CROHN'S DISEASE

Contacts and locations

Locations

Nanfang Hospital of Southern Medical University /ID# 243386

Guangzhou, Guangdong, 510515, China
Nanjing Drum Tower Hospital /ID# 243385

Nanjing, Jiangsu, 210008, China
Peking University Third Hospital /ID# 242803

Beijing, Beijing Municipality, 100191, China
Ruijin Hospital, Shanghai Jiaotong University School of Medicine /ID# 243213

Shanghai, Shanghai Municipality, 200065, China
Sir Run Run Shaw Hospital of Zhejiang University School of Medicine /ID# 242801

Hangzhou, Zhejiang, 310018, China
Sun Yat-sen Memorial Hospital of Sun Yat-sen University /ID# 242798

Guangzhou, Guangdong, 510120, China
The Second Affiliated Hospital of Zhejiang University School of Medicine /ID# 242802

Hangzhou, Zhejiang, 310009, China
The Sixth Affiliated Hospital of Sun Yat-sen University /ID# 242799

Guangzhou, Guangdong, 510655, China
West China Hospital, Sichuan University /ID# 242804

Chengdu, Sichuan, 610041, China
Zhejiang Provincial Hospital of Chinese Medicine /ID# 243443

Hangzhou, Zhejiang, 310006, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.